Literature DB >> 11740049

Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas.

K H Ruebel1, L Jin, S Zhang, B W Scheithauer, R V Lloyd.   

Abstract

Recent studies have shown that methylation of the CpG island within the p16/CDKN2A/MTS1 (p16) gene is associated with loss of expression of p16 protein in pituitary tumors. We analyzed a series of 21 pituitary adenomas and three normal pituitaries along with a human pituitary cell line (HP75) for methylation of exon 1 by methylation-specific PCR, immunohistochemistry, and Western blotting. PCR analysis showed that 5/7 (71%) of null cell adenomas, but only 2/7 (29%) gonadotroph tumors were hypermethylated. In addition,1 of 2 ACTH tumors but no GH (n = 4) or PRL (n = 1) adenoma examined were hypermethylated. Immunostaining and Western blot analysis of protein expression supported the methylation-specific PCR analyses. These results show that p16 gene silencing by hypermethylation is more common in null cell adenomas compared to other nonfunctioning adenomas such as gonadotroph tumors and that the role of p16 in the pathogenesis of pituitary adenomas is restricted to specific tumor subtypes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740049     DOI: 10.1385/ep:12:3:281

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  45 in total

1.  Frequent loss of the P16INK4a gene product in human pituitary tumors.

Authors:  M Woloschak; A Yu; J Xiao; K D Post
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

Review 2.  The cytogenesis and pathogenesis of pituitary adenomas.

Authors:  S L Asa; S Ezzat
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

3.  Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation.

Authors:  M Woloschak; A Yu; K D Post
Journal:  Mol Carcinog       Date:  1997-08       Impact factor: 4.784

Review 4.  Molecular pathogenesis of pituitary tumors.

Authors:  W E Farrell; R N Clayton
Journal:  Front Neuroendocrinol       Date:  2000-07       Impact factor: 8.606

5.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.

Authors:  J G Herman; A Merlo; L Mao; R G Lapidus; J P Issa; N E Davidson; D Sidransky; S B Baylin
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

6.  Analysis of pituitary hormones and chromogranin A mRNAs in null cell adenomas, oncocytomas, and gonadotroph adenomas by in situ hybridization.

Authors:  R V Lloyd; L Jin; K Fields; W F Chandler; E Horvath; L Stefaneanu; K Kovacs
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

7.  Ras mutations in human pituitary tumors.

Authors:  H J Karga; J M Alexander; E T Hedley-Whyte; A Klibanski; J L Jameson
Journal:  J Clin Endocrinol Metab       Date:  1992-04       Impact factor: 5.958

8.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Clonal origin of pituitary adenomas.

Authors:  V Herman; J Fagin; R Gonsky; K Kovacs; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

10.  p53 gene mutations in pituitary adenomas: rare events.

Authors:  A Levy; L Hall; W A Yeudall; S L Lightman
Journal:  Clin Endocrinol (Oxf)       Date:  1994-12       Impact factor: 3.478

View more
  5 in total

1.  Galectin-3 Expression in Functioning and Silent ACTH-Producing Adenomas.

Authors:  Long Jin; Dominik Riss; Katharina Ruebel; Sabine Kajita; Bernd W Scheithauer; Eva Horvath; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  Oncogene-Induced Senescence in Pituitary Adenomas--an Immunohistochemical Study.

Authors:  Emilija Manojlovic-Gacic; Milica Skender-Gazibara; Vera Popovic; Ivan Soldatovic; Novica Boricic; Savo Raicevic; Sandra Pekic; Mirjana Doknic; Dragana Miljic; Irina Alafuzoff; Fredrik Pontén; Olivera Casar-Borota
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

Review 3.  Best Practice No 172: pituitary gland pathology.

Authors:  J W Ironside
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

Review 4.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

Review 5.  The role of epigenetic modification in tumorigenesis and progression of pituitary adenomas: a systematic review of the literature.

Authors:  Matthew Pease; Chao Ling; William J Mack; Kai Wang; Gabriel Zada
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.